Staff editor
Francesca Ponziani from Gemelli University Hospital (Italy) highlights how the gut microbiota can become a clinical tool for identifying and stratifying patients, clarifying pathogenic mechanisms, and opening up new therapeutic…
Federica Facciotti, from University of Milano Bicocca, focuses on how the gut microbiota interacts with immune activation, shaping both chronic inflammatory intestinal disorders and oncology, particularly colorectal cancer.
Duccio Cavalieri, professor at the University of Florence, shifts the spotlight from bacteria to the less-explored fungal and yeast communities of the microbiome, highlighting their emerging role in shaping host…
Microbiomepost conducted an exclusive interview with George Paraskevakos, Executive Director at International Probiotic Association in order to discuss the global market of biotic products in 2025.
Ger T. Rijkers, University College Roosevelt, Netherlands, discusses the regulatory frame about probiotics in Europe.
Douwe Van Sinderen, professor of Molecular Microbiology at School of Microbiology & APC Microbiome Ireland, focuses on bacteriophages infecting lactic acid bacteria used in food and probiotic applications.
Immunology
Sponsored by
Three infant-derived strains isolated and developed by Coree srl that are potentially interesting for immune support.
Emilia Ghelardi, Professor of Microbiology and Molecular Microbiology at the University of Pisa, explains how pathogens can actively disrupt the integrity of the commensal community.
Arthur Ouwehand, Technical Fellow at IFF Finland, discusses the components and vulnerabilities of the gut barrier and reviews how probiotics and related dietary interventions can support its structure and function.
MaaT Pharma, based in Lyon and listed on Euronext Paris, unveiled the final results of its ARES Phase 3 trial of Xervyteg® (MaaT013).
